White Label Rx pricing vs pass-through: which model fits a clinic?

Quote-driven pricing can win when a clinic's volume is high enough to extract aggressive negotiated rates, and when the buyer is comfortable committing before seeing per-vial cost. The upside is concentrated buying power; the risk is that the rate is unverifiable up front and may pair with fees or minimums that change landed cost. Pass-through pricing wins when a clinic needs to quote cash-pay patients on landed cost before the consult, wants to verify that drug cost is not marked up, and values seeing the number on every SKU before ordering. Its limit is that it depends on the underlying 503A cost rather than a separately negotiated discount.

Most cash-pay clinics care most about one thing: knowing per-vial cost before they set patient pricing. That single requirement tends to favor a pass-through model, because a quote that arrives after onboarding cannot inform pricing you need to set during evaluation. But a high-volume operation already comfortable with negotiated contracts may rationally prefer the quote path — the right answer depends on the clinic, not the marketing.

Do not decide on model labels; decide on landed cost for your real SKUs. Get an itemized White Label Rx quote that separates drug cost from any fees on your top three SKUs, then open a pass-through catalog and read the visible per-vial cost plus disclosed facilitation fee on the same drug, strength, and vial size. Normalize both to delivered per-vial cost, including shipping and any platform fee, over a representative month.

With Fizy Health you can do half of that comparison immediately, because it shows resolved per-vial 503A cost on each catalog and cart line before checkout and discloses a single facilitation fee at payment. Build a representative cart, read the totals, and set that against your White Label Rx quote. Whichever model delivers lower true landed cost on the SKUs you actually order is the right choice — and now you can prove it rather than assume it.